Ani Pharmaceuticals (ANIP) Assets Average (2011 - 2026)

Ani Pharmaceuticals has disclosed Assets Average across 16 years of filings, most recently posting $1.5 billion for Q2 2026.

• In Q2 2026, Assets Average rose 10.65% year-over-year to $1.5 billion; the TTM figure through Jun 2026 stood at $1.5 billion (up 10.65% YoY), while the FY2025 annual figure was $1.4 billion, up 24.49% from the prior year.
• Assets Average came in at $1.5 billion for Q2 2026 at Ani Pharmaceuticals, up from $1.4 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.5 billion in Q2 2026 to a low of $745.2 million in Q3 2022.
• Average Assets Average over 5 years is $1.0 billion, with a median of $913.6 million recorded in 2024.
• Year-over-year, Assets Average jumped 63.93% in 2022 and grew 0.58% in 2023.
• Over 5 years, Assets Average stood at $749.6 million in 2022, then gained by 19.69% to $897.2 million in 2023, then soared by 43.33% to $1.3 billion in 2024, then grew by 10.76% to $1.4 billion in 2025, then gained by 2.37% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $1.5 billion in Q2 2026, $1.4 billion in Q1 2026, and $1.4 billion in Q4 2025.